AstraZeneca and Global Transparency
Our Approach
AstraZeneca strongly believes that interactions with Health Care Providers (HCPs) and Healthcare Organisations (HCOs) positively influence the quality of patient treatment and the value of medical research.
To provide patients with optimal treatment options, HCPs need to stay informed about the latest developments with current and potential new medicines. The pharmaceutical industry has a duty to provide this information.
HCPs in turn provide the industry with insights into how to improve medicines by feeding back on how they work in real world settings.
We also recognize that patients expect transparency around these relationships to feel confident that HCPs are impartial and always recommend the most appropriate treatment options.
We believe that regulations such as US Open Payments, the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure code, and others across the globe, which require companies to disclose payments and transfers of value made to HCPs and HCOs, will provide greater transparency around these already well-regulated relationships.
Disclosure of Payments and Transfers
The payments and transfers of value disclosed here were made for activities such as providing professional advice about how medicines are used in practice, sharing professional expertise at medical education meetings, taking part in advisory boards, research and educational grants.
Europe
To download the assumptions and interpretations of the Disclosure Code for each of our markets, and to download market-level disclosure reports, please click on the country links below.
The EFPIA Disclosure Code 2019 Self Certification Letter affirms AstraZeneca’s commitment to the principles of the EFPIA Disclosure Code.
Austria
2019
2018
2017
2016
Belgium
2019
2018
2017
2016
Bulgaria
2019
2018
2017
2016
Croatia
2019
2018
2017
2016
Cyprus
Transparency obligations have been fulfilled per local requirements. Disclosures by KEFEA Members and other EFPIA members operating in Cypress can be found via the following link: http://kefea.org.cy/disclosure-new/
Czech Republic
2019
2018
2017
2016
Denmark
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Estonia
2019
2018
2017
2016
Finland
2019
2018
2017
2016
France
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link: https://www.transparence.sante.gouv.fr/
Transparency obligations have also been fulfilled per EFPIA requirements as it relates to Global transfers of value. Disclosures can be found via the following links:
2019
2019 France EFPIA Disclosure Summary report
2018
2018 France EFPIA Disclosure Summary report
2017
2017 France EFPIA Disclosure Summary report
Germany
Greece
2019
2018
2017
2016
Hungary
2019
2018
2017
2016
Iceland
There are no payments/transfers of value to disclose.
Ireland
2019
2018
2017
2016
Italy
Latvia
2019
2018
2017
2016
Lithuania
2019
2018
2017
2016
Luxembourg
2019
2018
2017
2016
Malta
Netherlands
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link: https://www.transparantieregister.nl/en-gb/home
Norway
2019
2018
2017
2016
Poland
2019
2018
2017
2016
Portugal
Romania
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Russia
2019
2018
2017
2016
Serbia
2019
2018
2017
2016
Slovakia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Slovenia
2019
2018
2017
2016
Spain
Sweden
2019
2018
2017
2016
Switzerland
2019
2018
2017
2016
Turkey
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Ukraine
2019
2018
2017
2016
United Kingdom
2019
Transparency obligations have been fulfilled per local requirements. Disclosures can be found via the following link: www.disclosureuk.org.uk
US
For information about US Open Payments, please visit our Physician engagement page or the US Open Payments page managed by the Centers for Medicaid and Medicare Services (CMS).
Alternatively, for information regarding other US specific disclosure activity, please visit the US Corporate Transparency page.
Asia Pacific
Australia
HCP Payments and Transfers of Value Report
Sponsorship of Third Party Educational Events Report
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Health Consumer Organisations Report
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Indonesia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Japan
Philippines
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
South Korea
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Latin America
Brazil State of Minas Gerais
Mexico
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Middle East & Africa
Saudi Arabia
Transparency obligations have been fulfilled per local requirements. Inquiries may be submitted to the Global Payment Transparency team at Global-Payment-Transparency@astrazeneca.com.
Last updated June 2020